Nectero Medical
Nectero Medical is a clinical-stage biotech company pioneering novel therapies for aneurysmal disease, with a focus on developing minimally invasive treatments for small to medium-sized abdominal aortic aneurysms (AAA). Their mission is to improve patient outcomes by offering innovative, less invasive options that can slow or stabilize aneurysm growth and potentially prevent rupture.
Industries
Nr. of Employees
small (1-50)
Nectero Medical
1155 W. Rio Salado Pkwy, Suite B-104, Tempe, AZ 85281
Patents
Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US-9889279-B2
View Details
Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US-9889279-B2
View DetailsProducts
Nectero EAST® System
A minimally invasive treatment for small to mid-sized abdominal aortic aneurysms, using a dual-balloon catheter to deliver a stabilizer mixture to strengthen the aortic wall.
stAAAble Trial
A clinical trial to evaluate the safety and efficacy of the Nectero EAST® System in patients with infrarenal abdominal aortic aneurysms.
Nectero EAST® System
A minimally invasive treatment for small to mid-sized abdominal aortic aneurysms, using a dual-balloon catheter to deliver a stabilizer mixture to strengthen the aortic wall.
stAAAble Trial
A clinical trial to evaluate the safety and efficacy of the Nectero EAST® System in patients with infrarenal abdominal aortic aneurysms.
News & Updates
Nectero Medical was granted Breakthrough Therapy designation by the FDA for the Nectero EAST® System, which aims to treat infrarenal AAAs with a maximum diameter of 3.5 – 5.0cm. The system is an investigational, single-use, endovascular device designed to deliver a proprietary mixture to strengthen the aortic wall and reduce degradation, potentially delaying or preventing rupture.
The FDA granted Fast Track designation to Nectero Medical for their EAST® System, an investigational treatment for small to mid-sized AAAs, to facilitate development and expedite review.
Nectero Medical received the AZBio Fast Lane Award in 2024, recognizing their progress in developing health innovations in Arizona.
Nectero Medical was granted Breakthrough Therapy designation by the FDA for the Nectero EAST® System, which aims to treat infrarenal AAAs with a maximum diameter of 3.5 – 5.0cm. The system is an investigational, single-use, endovascular device designed to deliver a proprietary mixture to strengthen the aortic wall and reduce degradation, potentially delaying or preventing rupture.
The FDA granted Fast Track designation to Nectero Medical for their EAST® System, an investigational treatment for small to mid-sized AAAs, to facilitate development and expedite review.
Nectero Medical received the AZBio Fast Lane Award in 2024, recognizing their progress in developing health innovations in Arizona.